NFKB1 and Nephropathy: In a recent study, we have found that therapeutic treatment with an anti-IL-17A neutralizing antibodies, starting after nephropathy, had already developed, improved kidney dysfunction and decreased kidney NF-κB activation, proinflammatory factors and inflammatory cell infiltration in experimental diabetic nephropathy in BTBR ob/ob (leptin deficiency mutation) mice (Lavoz et al., 2019), a model that uniformly develops human diabetic nephropathy features (Hudkins et al., 2010).